Russell Investments Group
SMMT icon

Russell Investments Group’s Summit Therapeutics SMMT Stock Holding History

Russell Investments Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$607K Buy
41,693
+23,707
+132% +$420K ﹤0.01% 2691
2026
Q1 		$341K Buy
17,986
+1,020
+6% +$16.5K ﹤0.01% 2655
2025
Q4 		$297K Sell
16,966
-41,133
-71% -$774K ﹤0.01% 2686
2025
Q3 		$1.2M Sell
58,099
-145,779
-72% -$3.54M ﹤0.01% 2132
2025
Q2 		$4.34M Sell
203,878
-7,126
-3% -$163K 0.01% 1303
2025
Q1 		$4.07M Buy
211,004
+141,664
+204% +$2.84M 0.01% 1275
2024
Q4 		$1.24M Sell
69,340
-20,801
-23% -$403K ﹤0.01% 1906
2024
Q3 		$1.97M Buy
90,141
+83,085
+1,178% +$1.16M ﹤0.01% 1693
2024
Q2 		$55K Buy
7,056
+960
+16% +$5.18K ﹤0.01% 2742
2024
Q1 		$25.2K Buy
6,096
+3,579
+142% +$14.2K ﹤0.01% 2746
2023
Q4 		$6.57K Hold
2,517
– – ﹤0.01% 2873
2023
Q3 		$4.71K Buy
+2,517
New +$4.8K ﹤0.01% 3154
2022
Q1 		– Sell
-216,991
Closed -$582K – 2914
2021
Q4 		$582K Buy
216,991
+129,578
+148% +$623K ﹤0.01% 2388
2021
Q3 		$437K Buy
+87,413
New +$627K ﹤0.01% 2522

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Russell Investments Group's SMMT Position: Q2 2026 in Review

Russell Investments Group increased its Summit Therapeutics (SMMT) stake by 132% in Q2 2026, buying an estimated $420K and bringing the position to 41,693 shares worth $607K. The position accounts for ﹤0.01% of the portfolio, ranked #2691.

Russell Investments Group first reported a position in SMMT in Q3 2021 and has held it in 14 quarters since. The position peaked at $4.34M in Q2 2025. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Russell Investments Group held 41,693 shares of Summit Therapeutics worth $607K as of Q2 2026.
  • Russell Investments Group bought 23,707 Summit Therapeutics shares in Q2 2026, an estimated $420K.
  • Summit Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2691 holding.
  • Russell Investments Group first reported a position in Summit Therapeutics in Q3 2021 and has held it in 14 quarters since.
  • Russell Investments Group's Summit Therapeutics position peaked at $4.34M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.